News
Kuros Biosciences announces successful CHF 6.0 million private placement
Relief Reports Half-Year 2022 Results and Provides Corporate Update
Relief Therapeutics to Participate in the 22nd Annual Biotech in Europe Forum
Relief Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
Lonza and Touchlight collaborate on end-to-end mRNA offering
GeNeuro : Two Studies on ALS Published in Annals of Neurology Demonstrate the Neurotoxic Role of Human Endogenous Retrovirus Envelope Protein (HERV-K/HML-2 ENV) and the Rationale for Targeted Therapy With Specific Antibody
GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases such as multiple sclerosis (MS), amyotrophic
DGAP-News: BB BIOTECH AG: Moderna was just the beginning
Evolva with record half-yearly sales and new mid-term plan
Relief Therapeutics files registration statement on form F-1 with the U.S. Securities and Exchange Commission
Kuros Biosciences’ MagnetOs Bone Graft Successfully Achieves Three Key Milestones
CSL Vifor and Travere Therapeutics announce EMA has accepted for review the Conditional Marketing Authorization application for sparsentan for the treatment of IgA Nephropathy
CSL Vifor and Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the EMA has accepted for review the Conditional Marketing Authorization (CMA) application for sparsentan for the
VFMCRP announces U.S. Court upholds validity of Velphoro® patent
Vifor Fresenius Medical Care Renal Pharma (VFMCRP) today announced that the U.S. District Court for the District of Delaware issued a judgment in VFMCRP’s favor regarding U.S. patent no. 9,561,251
Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. announce tentative settlement of pending litigation
Kapruvia® approved in Switzerland with additional regulatory decisions expected in H2 2022
Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that they have received approval for Kapruvia® from the Swiss Agency for Therapeutic
Tavneos® (avacopan) recommended by England’s NICE for the treatment of AAV (GPA/MPA)
Vifor Fresenius Medical Care Renal Pharma (VFMCRP) is pleased to announce that England’s National Institute for Health and Care Excellence (NICE) has recommended Tavneos® in combination with a
Relief Therapeutics Appoints David McCullough as Head of U.S. Market Access
Relief Therapeutics and Acer Therapeutics Announce that the European Commission Has Granted Orphan Drug Designation for ACER-001 in Maple Syrup Urine Disease
Kuros Biosciences reports results for the first six months of 2022
Relief Therapeutics Announces Promising Initial Stability Data on a New Formulation of RLF-100® (Aviptadil)
Finalization of Vifor Pharma acquisition
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220801005796/en/
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
CSL
Acer Therapeutics and Relief Therapeutics Announce ACER-001 IND Submission for the Treatment of Maple Syrup Urine Disease
Acer Therapeutics and Relief Therapeutics Announce FDA Acceptance for Review of NDA Resubmission for ACER-001 for Treatment of UCDs
Evolva with strong business momentum in 1H 2022, announcing targets of mid-term plan
DGAP-Adhoc: BB Biotech AG publishes its interim report